Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCE-MRI Guided Hypofractionated Radiotherapy in Locally Advanced NSCLC
NCT06545747Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2024
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoints: Treatment-related G2+ respiratory toxicity at 1 year and Progression-Free Survival Rate at 2 years. Started Aug 2024; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06545747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06545747.